Abecma is a Intravenous Suspension in the Cellular Therapy category. It is labeled and distributed by Celgene Corporation. The primary component is Idecabtagene Vicleucel.
| Product ID | 59572-515_1d76d5fe-64a7-4b3b-8675-bcf43bdb7ed7 |
| NDC | 59572-515 |
| Product Type | Cellular Therapy |
| Proprietary Name | Abecma |
| Generic Name | Idecabtagene Vicleucel |
| Dosage Form | Suspension |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2021-03-26 |
| Marketing Category | BLA / |
| Application Number | BLA125736 |
| Labeler Name | Celgene Corporation |
| Substance Name | IDECABTAGENE VICLEUCEL |
| Active Ingredient Strength | 300000000 1/1 |
| NDC Exclude Flag | N |
| Listing Certified Through | 2023-12-31 |
| Marketing Start Date | 2021-03-26 |
| NDC Exclude Flag | N |
| Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() ABECMA 90300803 not registered Live/Pending |
Celgene Corporation 2020-11-05 |
![]() ABECMA 90300795 not registered Live/Pending |
Celgene Corporation 2020-11-05 |
![]() ABECMA 88578888 not registered Live/Pending |
Celgene Corporation 2019-08-14 |
![]() ABECMA 88202247 not registered Live/Pending |
Celgene Corporation 2018-11-21 |